showed a trendp = 0.08
Note that Chronos animals only showed a trend towards hyperlocomotion during the stimulation in this case (Fig. 3h ; D(28) = 1.27, p = 0.08; Kolmogorov-Smirnov Z Test).
Note that Chronos animals only showed a trend towards hyperlocomotion during the stimulation in this case (Fig. 3h ; D(28) = 1.27, p = 0.08; Kolmogorov-Smirnov Z Test).
Analysis of the frequencies of mDCs and non-classical monocytes in the PLN showed a trend ( p = 0.08, Spearman's rank) toward correlating with higher levels of viral loads in this tissue, but fell short of statistical significance (Fig. 4d ).
In our study, patients aged between 50 and 70 years showed a trend toward a better PFS rate at 36 months (OR = 1.65, 95% CI [0.93–2.91], p = 0.08) when compared to older patients, although the difference was not statistically significant.
qMRI showed a trend toward higher concordance with the gold standard (subjective worsening) compared with anatomical MRI (p = 0.08), whereas differences with mJOA (p = 0.55) and comprehensive clinical assessments (p = 0.75) were non-significant.
Two RCTs showed similar efficacy between EBL and EVO for treating GOV1 bleeding [ 201 , 231 ], another RCT showed a trend toward higher hemostasis rate in the EVO group compared to the EBL group (85% vs. 43%, P =0.08) [ 44 ].
FSHD2 patients showed a trend to express more ACVRIIB than FSHD1 (+120%, p = 0.08).
HER2+/HR− tumors showed a trend toward significantly higher TIL levels compared to HR+ tumors (mean 14.3 vs 11.9, p = 0.08).
However, the I-PD-L1 (+) group showed a trend of advantage in survival over the I-PD-L1 (−) group ( p = 0.080) (Figure 3B ).
This effect was less significant at day 21 but still showed a trend toward reduced mortality compared with the SMT group ( p = 0.080) ( Table 2 ).
RMG showed a trend to be lower in LP compared to NP (p<0.08) at PND 10 and 12.
This might be partially due to the BO-Condition showing large RT-differences between regular and deviant trials from Block 1 on [ F (1, 37) = 17.68, p < 0.001, η p 2 = 0.323] whereas the RO- Condition merely showed a trend of an increasing difference between regular and deviant trials, when comparing Block 1 with Block 6 [ F (1, 37) = 3.24, p = 0.080, η p 2 = 0.081].
A one-way ANOVA comparing the four taste groups was not statistically significant, but showed a trend towards possible differences across the taste groups (F(3,196) = 2.2, p = .08).
mRNA expression of collagen type I α 1 chain (COL1A1) showed a trend in being up-regulated following TGF-β1 treatment with mean FC = 4.8 ( P = 0.08) for control fibroblasts ( Figure 6 L) and mean FC = 6.6 ( P = 0.09) for IPF fibroblasts ( Figure 6 L) compared with corresponding untreated fibroblasts (FC = 1). α-Smooth muscle actin (encoded by gene ACTA2 ), a component of the cytoskeleton, is a marker of fibroblast activation to a contractile, ECM-producing phenotype.
Ki-67 index ≥ 14% showed a trend toward an association with a higher IBTR rate (5-year IBTR rate: 1.4%) compared with Ki-67 index < 14% (5-year IBTR rate: 0%) in this group ( P = 0.08).
The other tested matrix-metalloproteinase MMP9 also showed a trend between these two groups, 0.39 ± 0.21 versus 1.14 ± 0.34 respectively, p < 0.08.
Also, APOBEC3B mRNA levels measured in distant metastases ( N = 35) showed a trend towards higher expression when compared to regional lymph node metastases ( N = 20) of unmatched cases (Mann-Whitney U test P = 0.08, Fig 2A ).
Both edoxaban doses demonstrated noninferiority to VKA in reducing the risk of stroke or SE in the primary analysis, including patients in the intent-to-treat population who received study drug during the treatment period (annual rates of 1.61%, 1.18%, and 1.50% for low-dose edoxaban, high-dose edoxaban, and warfarin, respectively); high-dose edoxaban showed a trend toward better efficacy vs warfarin in a prespecified superiority analysis of the intent-to-treat population during the entire study period (1.57% vs 1.80%; P =0.08). 29 In Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), 18,201 patients (mean CHADS 2 score 2.1; median age 70 years) were randomized to apixaban 5 mg twice daily (2.5 mg doses were used in patients with two or more of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine level ≥1.5 mg/dL) or warfarin.
The number of red-listed staging spring migrants showed a trend indicating a positive correlation with the total cost of wetland management (b = 0.000009, F 1,31 = 3.28, P = 0.08).
In multivariable Cox analysis, a higher radiomics score showed a trend toward shorter RFS [hazard ratios (HRs) 1.46 per SD increase, P=0.08].
Participants with the lowest quartile mean SF36 score showed a trend towards a positive effect of the supplement (V1: 626, V2: 663, p = 0.08).
Quantitative analysis of the hand joints of all 20 patients showed a trend of higher 89 Zr-rituximab joint uptake in responders than in non-responders (SUV, p = 0.08; T/B ratio, p = 0.06).
In fact, funnel plots were created for each study outcome, and the tests of asymmetry showed a trend for mortality ( P = 0.08), although the data were not significant for overall infections ( P = 0.19), hospital LOS ( P = 0.50), or MV days ( P = 0.37).
In overweight children, these parameters showed a trend toward statistical significance ( p = 0.080, p = 0.093, p = 0.074, and p = 0.052, respectively).
When stratified by the median of age (w-GRS*age p = 0.001 and p = 0.02 for SNP group#1 and #2, respectively) individuals older than 54 years old had 0.23 BMI unit increase per additional risk allele and an explained BMI variability of 2.74% whereas those at 54 years or younger showed a trend of 0.10 units increase and 0.56% of explained BMI variability after multiple test correction (p = 0.08).
Point by point comparisons between groups showed a trend in lower values for OB compared to CT at 0700h, 0900h and 1900h (p = 0.08).